Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Gigacloud Technology Inc (GCT) Price & Performance

ADMA Biologics IncTrade
Gigacloud Technology IncTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Gigacloud Technology Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.22B), while Gigacloud Technology Inc trades at $51 (market cap $1.84B). The key difference: ADMA Biologics Inc is the larger of the two by market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.

ADMAGCT
Market Cap
$2.22B$1.84B
Sector
HealthTechnology
52-Week High
$20.38$53.25
52-Week Low
$7.60$25.44
Enterprise Value
$2.29B$1.97B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

Gigacloud Technology Inc

GCT trades at $53.25, up 1.62% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.16 versus $0.90 expected, and maintains a 10.65% net income margin. Revenue growth is projected from $1.29B in 2025 to $1.5B in 2026, supported by positive cash flow generation of $120.10M in 2025.

The outlook remains positive given strong profitability metrics (32.34% ROE) and analyst consensus favoring Buy ratings (66.67%). Key risks include potential margin pressure from higher costs and competitive threats in the B2B logistics space. The stock's current valuation at 12.3x P/E appears reasonable relative to growth prospects, though technical indicators show overbought conditions with RSI above 85.

Returns comparison

Trailing returns across standard periods

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Gigacloud Technology Inc

Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.

Read more on GCT